Once daily application of a combination of calcipotriol and betamethasone dipropionate (Dovobet, Daivobet) for the treatment of psoriasis.
D000328:Adult; D001623:Betamethasone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D002117:Calcitriol / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D016001:Confidence Intervals; D003627:Data Interpretation, Statistical; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004338:Drug Combinations; D006801:Humans; D015337:Multicenter Studies as Topic; D010349:Patient Compliance; D011446:Prospective Studies; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D013997:Time Factors
D003879:Dermatologic Agents; D004338:Drug Combinations; C055085:calcipotriene; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D002117:Calcitriol